Researchers found that production of the cytokine IL-15 by fibroblastic reticular cells was essential for the maintenance of group 1 innate lymphoid cells (ILCs) in Peyer’s patches and mesenteric lymph nodes. [Nat Immunol]
Abstract

The authors found that interleukin-2 cytokine/antibody complex (IL2c) treatment rescued tumor-specific CD8+ T cells from a state of established tolerance, providing effective immunotherapy in tumor-bearing mice. Expression of the transcription factor T-bet was necessary to drive intratumoral IFNγ production and effector activity by T cells rescued with IL2c. [Cancer Immunol Res]
Abstract

The authors infected eosinophil-deficient ΔdblGATA-1 mice with the type 2 helper T (Th2)-inducing small intestinal nematode Heligmosomoides polygyrus and found that parasite fecundity was decreased in the absence of eosinophils. A lack of eosinophils resulted in significantly augmented expression of GATA-3 and IL-4 by CD4+ T cells during acute infection, a finding strictly limited to Peyer’s patches. [Mucosal Immunol]
Abstract

The authors focus on the role of programmed cell-death protein 1/programmed cell death 1 ligand 1 (PD-1–PD-L1) blockade in unleashing host antitumor immune responses against various B-cell lymphomas, and summarize the clinical studies of this approach performed to date. [Nat Rev Clin Oncol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the immune regulation research field.

Gov. Andrew Cuomo announced that a partnership formed during his historic New York State Trade Mission to Cuba last year has resulted in a milestone of international collaboration: the launch of a U.S. clinical trial of a Cuban immunotherapy developed by the Center of Molecular Immunology for lung cancer. [Roswell Park Cancer Institute]
Press Release

DNAtrix announced that the first patients have been treated in a multicenter Phase II trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with recurrent glioblastoma. [DNAtrix]
Press Release

Omeros Corporation announced that it has filed an application for orphan drug designation with the U.S. Food and Drug Administration for OMS721 in the treatment of immunoglobulin A nephropathy. [Omeros Corporation]
Press Release

As the United States goes to the polls after an unprecedentedly vulgar election campaign, its former cold-war rival is exuding strength and confidence. Just last week, Russia cited its proud history of exploration and science in Antarctica when giving the green light to an international agreement to create a vast marine reserve in the Ross Sea. [Nature News]
Editorial

A tranche of 58 articles authored by 282 Iran-based researchers were retracted by a leading scientific publisher, which said it had found signs that the peer review and publication processes had been compromized. [Nature News]
Editorial

There is a vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs. Among the factors driving this change are an infusion of money into early-stage biotech investing, the emergence of biotech incubators and the scarcity of academic jobs in science. [Nature News]
Editorial

An automated tool has trawled through thousands of records on the world’s leading clinical-trials database to reveal which drug firms and academic institutions are failing to publish the results of their trials. The US Department of Health and Human Services announced tougher rules to push the researchers that it funds to publish clinical-trial designs and results. [Nature News]
Editorial